Village Farms: A 75% Trim Collapse, a Texas Option, and the Price of 'Not Cutting Prices'
The two markets inside one call
Village Farms delivered a genuinely good top line and a technically awkward bottom line. Cannabis revenue hit a record $55 million, with international export sales up 75% year over year to $20.8 million — roughly 43% of segment sales from the fastest-growing regulated markets on earth. Yet consolidated gross margin fell to 44% from 48%, and cannabis gross margin dropped to 48% from 55%. The explanation is a single, brutal Canadian dynamic: “spot trim pricing down about 75% year over year during the quarter” — Michael A. DeGiglio, Chief Executive Officer · 2026-11-09. Management calls Q3 the trough and points to an October order book plus newly signed trim supply agreements at "more in line with historical levels" pricing to argue normalization in Q4.
That bifurcation — pharmaceutical-grade export flower holding price while commodity trim collapses — is the whole thesis in miniature. And it is precisely where the call gets interesting, because the market's skepticism has a specific shape.
'We have not lowered pricing' — a six-quarter refrain now under margin pressure
Mike DeGiglio was emphatic: “let me be clear, we have not lowered pricing for our EU GMP compliant product” — Michael A. DeGiglio, Chief Executive Officer · 2026-11-09. That is a phrase with a long history here. In May 2026 he told analysts that “for our EU GMP certified product, we have not seen really any margin compression” — Mike DeGiglio, Chief Executive Officer · 2026-05-11; in August he repeated “we haven't seen a decline in our pricing” — Mike DeGiglio, Chief Executive Officer · 2026-08-10. Three calls, one claim — and yet the segment's gross margin has now compressed seven points year over year.
So read the fine print. The average net selling price declined 9% year over year, which management insists was entirely a mix shift to bulk flower rather than a price cut. Meanwhile the variance driven language around gross margin is doing a lot of work: softer price compression in Canada offset by healthier produce/clean-energy results. The honest read is that EU GMP list pricing may be holding while realized pricing per unit slips as customers buy lower-value bulk formats. That is a distinction that matters — and one analysts circled repeatedly. Ann Lefever's framing of the moat is the most defensible version of the argument: scale, consistency and a complex supply chain combine such that “that is a competitive moat that we have” — Hamid Shekarchi, Interim Financial Officer · 2026-11-09.
Canada: the quiet admission
The most under-discussed line of the quarter was a concession. Branded Canadian sales fell 6% to $25.3 million, and on a domestic business the CEO has repeatedly positioned as core, he said: “We have not achieved that goal in recent quarters, and we are not satisfied with that result” — Michael A. DeGiglio, Chief Executive Officer · 2026-11-09. That is a notable tonal shift from prior calls, where Canada was framed as a leading, share-gaining franchise. The bull comfort here is competitor exit — management says several players are de-emphasizing Canadian branded flower — and a federal single excise stamp plus crackdowns on the illicit market. But a shrinking domestic top line while you reallocate first-harvest Delta 2 flower to defend share is a growth-by-attrition story, not a growth story.
Texas: the thing that is actually new
Here the call pivoted from theme to action. After quarters of saying only that they “plan to be in Texas” — Mike DeGiglio, Chief Executive Officer · 2026-08-10, Village Farms went operational post-midterms:
we announced this morning that we are actively mobilizing plans to operationalize our stand alone 30-acre 1.3-million-square-foot greenhouse in Monahans, Texas for cannabis production
This is a company-unique keyword turn — a fresh THC ban backlash narrative where the incumbent who championed the ban was defeated, layered onto a national new Congress wave that the global tape has also been pricing. Management's pitch is operational: unlike Delta 2 conversions that take roughly six months, Monahans sits at the lowest latitude in the U.S., so no supplemental lighting is needed through winter — a structural cost edge. The catch is obvious: no license yet, and the whole gambit rides a February legislative session and a possible Schedule 3 rescheduling. They are pre-building an option, not a revenue line.
The adjacent Delta 1 greenhouse optionality — 25% conversion rights exercisable for 2027, roughly 50–60 metric tons — plus the pending Delta 2 full 40-ton run rate by mid-2027, means capacity is ahead of contracted demand. That is a good problem until it isn't; the company's leverage to demand is entirely dependent on EU GMP compliant supply staying scarce as UK and Hesse regulators tighten conversion pathways.
The balance sheet, and what to watch
Financially this remains a small-cap optionality story rather than a compounding machine. With a market cap near $352 million and the stock up 44% in ninety days after a brutal multi-year drawdown, the equity is already voting on policy. The cash story is genuinely improved: management ended Q3 with $80 million in cash and a $41 million net cash position, with an undrawn revolver — a real advance from the $28M effective net cash reported in the most recent 10-Q. Valuation on trailing sales sits around 1.1x price to revenue, and the 10.6x price to net income is a thin, lumpy base.
Three tests over the next two quarters. First, does trim actually normalize — or was Q3 the first leg lower? Second, does EU GMP enforcement in the UK and Hesse convert into the shortage management forecasts, and does the company's route to market hold as it moves beyond FOB distributors toward vertical integration, a path it has dangled but keeps punting on valuations it calls "crazy"? Third, does the February Texas session deliver a license pathway. Note the seasonality warning management volunteered: Q4 produce peaks reverse and European orders slow over the holidays. On a stock that just ran 44% into a policy thesis, the gap between a mobilized greenhouse and a licensed one is where the next chapter gets written.